Citadel Fine Pharmaceuticals Private Limited
About Citadel Fine Pharmaceuticals Private Limited
Data last updated:
Citadel Fine Pharmaceuticals Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 August 1966 and has been in existence for over 60 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U24231TN1966PTC005441. The company has 2 GST registrations on record, none of which is active.
The company has an authorised share capital of ₹75 Lakh and a paid-up capital of ₹22 Lakh. It is led by directors including Ramkumar Krishnamurthy Anekar and Rajiv Krishnamurthy.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 43 Main Rd Velachery Post Madras – 42., Chennai, Tamil Nadu, India – 600042.
As per the financials filed for FY 2024, the company reported a revenue of ₹15.31 Lakh, a decline of 1% compared to the previous year. For the same year it recorded a net profit of ₹1.67 Lakh (net margin 10.9%) and EBITDA of ₹5.46 Lakh (EBITDA margin 35.7%). Revenue has grown at a compounded annual rate (CAGR) of 1% over three years and 4% over five years.
As per MCA filings, the company has satisfied charges of ₹11.22 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Citadel Fine Pharmaceuticals Private Limited's registered office is in Chennai, Tamil Nadu. Its e-mail address is in the company report.
- Email
- Registered Address43 Main Rd Velachery Post Madras – 42., Chennai, Tamil Nadu, India – 600042
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Citadel Fine Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Citadel Fine Pharmaceuticals is hospital and medical care. In detail, this covers other hospital and medical care activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities |
Financials of Citadel Fine Pharmaceuticals Private Limited
FY 2025 filings availableCitadel Fine Pharmaceuticals Private Limited reported revenue of ₹15.31 Lakh (down 1% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 1% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 4%. EBITDA fell 10% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5.46 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.67 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 35.7% | ||||
| Net Profit Margin | 10.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Citadel Fine Pharmaceuticals Private Limited, buy the company report.
Board of directors of Citadel Fine Pharmaceuticals Private Limited
Citadel Fine Pharmaceuticals has 4 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ramkumar Krishnamurthy Anekar Also directs: Anekar Agrotech Private Limited, Integral System and Components Private Limited, Suman Controls Private Limited and 1 more | Director | 05 Oct 2005 | 21 Years 1 Months | Current |
| Rajiv Krishnamurthy Also directs: Citadel Aurobindo Biotech Limited | Director | 05 Oct 2005 | 21 Years 1 Months | Current |
| Ramesh Puthigai Krishnamurthy Also directs: Pranam Health Private Limited | Director | 01 Feb 1988 | 38 Years 9 Months | Current |
| Ranjan Rao Machina | Director | 21 Jun 1996 | 30 Years 4 Months | Current |
Auditor
Citadel Fine Pharmaceuticals Private Limited is audited by S VENKATRAM & CO for the financial year 2020.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S VENKATRAM & CO | FY 2020 | 004656S |
Shareholding
The shareholding of Citadel Fine Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2020, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2020 | FY 2019 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Citadel Fine Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Apr 2003 | 90295454 | State Bank of India | ₹2 Cr | Satisfied | |
| 15 Mar 1997 | 90295568 | State Bank of India | ₹1.92 Cr | Satisfied | |
| 25 Feb 1995 | 90296945 | State Bank of India | ₹2.1 Cr | Satisfied | |
| 30 Mar 1992 | 90297556 | State Bank of India | ₹1.8 Cr | Satisfied | |
| 26 Apr 1990 | 90296824 | State Bank of India | ₹1.13 Cr | Satisfied |
To see the full charge records of Citadel Fine Pharmaceuticals Private Limited, buy the company report.
Total charge records: 15 View all charges
Legal cases
No court or tribunal cases involving Citadel Fine Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Citadel Fine Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Citadel Fine Pharmaceuticals has 2 GST registrations on record, and all of them have been cancelled or are inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Citadel Fine Pharmaceuticals Private Limited, buy the company report.
Recent activity
Citadel Fine Pharmaceuticals Private Limited has 5 board changes on record since 1988: 4 appointments and 1 cessation. The latest: Padmanoor Harihara Rao Rajendra Rao ceased to be Director on 08 Feb 2022.
33 earlier events are in the company report.
Frequently asked questions
Citadel Fine Pharmaceuticals is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 August 1966 (60+ years old) and is registered under CIN U24231TN1966PTC005441.
Citadel Fine Pharmaceuticals has 4 current directors:
- Ramkumar Krishnamurthy Anekar - Director
- Rajiv Krishnamurthy - Director
- Ramesh Puthigai Krishnamurthy - Director
- Ranjan Rao Machina - Director
The latest financial statements of Citadel Fine Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
No. Citadel Fine Pharmaceuticals has 2 GST registrations on record and all of them are cancelled or inactive.
The CIN (Corporate Identification Number) of Citadel Fine Pharmaceuticals is U24231TN1966PTC005441. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Citadel Fine Pharmaceuticals was incorporated on 06 August 1966, making it 60+ years old. It is registered with the Registrar of Companies, Chennai.
Padmanoor Harihara Rao Rajendra Rao ceased to be Director on 08 Feb 2022. Rajiv Krishnamurthy was appointed as Director on 05 Oct 2005. Ramkumar Krishnamurthy Anekar was appointed as Director on 05 Oct 2005. Citadel Fine Pharmaceuticals has 5 board changes on record in total.
The registered office of Citadel Fine Pharmaceuticals is at 43 Main Rd Velachery Post Madras – 42., Chennai, Tamil Nadu, India – 600042.
Citadel Fine Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Citadel Fine Pharmaceuticals has no open charges and satisfied charges of ₹11.22 Cr as per latest MCA filings.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
